GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to jointly develop and market a monoclonal antibody, EOS-448, as a potential cancer treatment.

A human IgG1 antibody, EOS-448 is created to attach with high-affinity T cell immunoglobulin and ITIM domains (TIGIT). It has a multifaceted mechanism that induces an antitumor response.

According to the partnership terms, iTeos will get an upfront payment of $625m from GSK.

iTeos is also eligible for up to $1.45bn in potential milestone payments if the EOS-448 programme meets specific development and commercial milestones.

The worldwide development works of EOS-448 and expenses will be shared by both the companies, which will co-market the antibody in the US and split profits equally.

Furthermore, GSK will obtain an exclusive licence to market EOS-448 outside of the US and will pay tiered royalties to iTeos.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adding EOS-448 data will aid GSK to become the only firm with antibodies that target all three known CD226 checkpoints – TIGIT via EOS-448, CD96 via GSK’608 and PVRIG via GSK’562.

Along with GSK’s approved anti-PD-1 therapy, Jemperli (dostarlimab), these potential immuno-oncology agents will be analysed in several new combinations to treat various cancer types.

GSK R&D president and chief scientific officer Dr Hal Barron said: “Immuno-oncology has transformed cancer care but unfortunately less than 30% of patients respond to treatment with the current leading immune checkpoint inhibitors.

“Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer.”

GSK and iTeos intend to commence trials of EOS-448 in combination with dostarlimab next year.

EOS-448 is presently in an open-label Phase I trial for treating advanced solid tumour patients.

iTeos president and CEO Michel Detheux said: “Inspired by the multifaceted mechanism of action of EOS-448 and promising early results in clinical trials, this collaboration allows us to accelerate and expand the clinical development of EOS-448.”

In February, GSK signed a binding agreement with Vir Biotechnology to expand its existing partnership to research and develop novel therapies for influenza and other respiratory viruses.